Evaluation of cervical screening at treatment of a vulvovaginal atrophy in periand postmenopausal women


Cite item

Abstract

Objective. Determination of effective application of vaginal complex estriol 0,2 mg/progesteron 2 mg/Lactobacillus casei rhamnosus 2¥109 at women with a vulvovaginal atrophy in peri-and postmenopausal women with a evaluation of cervical screening. Materials and methods. 109 patients with a vulvovaginal atrophy (VVA) were examined: the 1st group - 53 patients in a perimenopauza (middle age - 50.11±3.89 years), the 2nd group - 56 women in a postmenopause at the age of 65.8±4.13 years. The complex of researches included an assessment of complaints, the anamnestic and clinical data, bakterioskopic, cytologic and kolposkopic researches with interpretation of results according to the International standards and use of the modern equipment. The medical stage included vaginal application of a complex estriol, progesterone, L. casei rhamnosus on the 2nd capsules once a day during 14 (in the 1st group) and 21 day (in the 2nd group). Control of cervical cytologic inspection was carried out twice (in 4 and 6 weeks) after treatment. Conclusions. After the carried-out local therapy at patients of two groups clinical improvement of a current of VVA, normalization of a biocenosis of a vagina in comparison with basic data is established (p<0.001). At patients of the 1st group normalization of cytologic dabs (NILM in 83% of cases) against a reduction of ASC-US, regression of an inflammation (is 5.6 times more often in comparison with basic data) and an atrophy was noted (3.7 times more often) (p<0.001); in the 2nd group - decrease in rates of normalization of cytologic dabs (NILM in 48% of cases), a full reduction of ASC-US (p<0.05) with a tendency to regression of an inflammation (by 1.9 times) and atrophies (1.3 times more often) than rather basic data.

About the authors

T V Klinyshkova

Omsk State Medical University of the Ministry of Health of the Russian Federation

Email: klin_tatyana@mail.ru
д-р мед. наук, проф. каф. акушерства и гинекологии ПДО ФГБОУ ВО ОмГМУ 644043, Russian Federation, Omsk, ul. Lenina, 12

I B Samosudova

Clinical diagnostic center «Ultramed»

Email: i.samosudova@mail.ru
канд. мед. наук, врач-акушер-гинеколог клин.-диагност. центра «Ультрамед» 644024, Russian Federation, Omsk, ul. Chkalova, d. 12

O N Mironova

Clinical diagnostic center

Email: mironova63gmail.com
врач выс. квалификационной категории клинической лабораторной диагностики патоморфологического отд. БУЗОО Клинический диагностический центр 644024, Russian Federation, Omsk, ul. Ilinskaia, d. 9

References

  1. Аполихина И.А., Горбунова Е.А. Клинико - морфологические аспекты вульвовагинальной атрофии. Медицинский совет. 2014; 9: 110-7.
  2. Балан В.Е., Ковалева Л.А. Симптомы и диагностика вагинальной атрофии. Шейка матки, влагалище, вульва. Физиология, патология, кольпоскопия, эстетическая коррекция: руководство для практикующих врачей. Под ред. С.И.Роговской, Е.В.Липовой. М.: Status Praesens, 2014; с. 747-8.
  3. Глазунова А.В., Юренева С.В., Ермакова Е.И. Вагинальная атрофия. Акушерство и гинекология. 2014; 2: 21-6.
  4. Kim H, Kang S, Chung Y et al. The Recent Review of the Genitourinary Syndrome of Menopause. Menopausal Med 2015; 21 (2): 65-71.
  5. Goldstein I, Dicks B, Kim N, Hartzell R. Multidisciplinary Overview of Vaginal Atrophy and Associated Genitourinary Symptoms in Postmenopausal Women. Sex Med 2013; 1 (2): 44-53.
  6. Parish S, Nappi R, Krychman M et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Womens Health 2013; 5: 437-47.
  7. Bride M, Rhodes D, Shuster L. Vulvovaginal Atrophy. Mayo Clin Proc 2010; 85 (1): 87-94.
  8. Domoney C. Treatment of vaginal atrophy. Womens Health (Lond Engl) 2014; 10 (2): 191-200.
  9. Lindahl S. Reviewing the options for local estrogen treatment of vaginal atrophy. Womens Health 2014; 6: 307-12.
  10. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации. Под ред. Л.В.Адамян, В.Н.Серова, Г.Т.Сухих, О.С.Филиппова. Проблемы репродукции (спец. выпуск). 2015; 6 (21): 459-1
  11. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Womens Health 2009; 1: 105-11.
  12. Reiter S. Barriers to effective treatment of vaginal atrophy with local estrogen therapy. Gen Med 2013; 6: 153-8.
  13. Brotman R, Shardell M, Gajer P et al. Association between the vaginal microbiota, menopause status and signs of vulvovaginal atrophy. Menopause 2014; 21 (5): 450-8.
  14. Di Bonaventura M, Luo X, Moffatt M et al. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health (Larchmt) 2015; 24 (9): 713-22.
  15. Tuntiviriyapun P, Panyakhamlerd K, Triratanachat S et al. Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? Climacteric 2015; 18 (2): 246-51.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).